
Bioventus, Inc. (($BVS)) has held its Q3 earnings call. Read on for the main highlights of the call. Bioventus’ earnings call was broadly constructive, with revenue growth, stronger profitability, solid
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| BVS | Bioventus | 10.95 | 3.73 | 51.65% |
| Name | Price | % Change | |
|---|---|---|---|
| $10.95 | +51.65% |

Bioventus, Inc. (($BVS)) has held its Q3 earnings call. Read on for the main highlights of the call. Bioventus’ earnings call was broadly constructive, with revenue growth, stronger profitability, solid

Alvotech ($ALVO), Zenas BioPharma, Inc. ($ZBIO), and Bioventus ($BVS) are three small-cap healthcare stocks that could offer more than 45% upside, according to Wall Street consensus price targets. These companies

Craig-Hallum lowered the firm’s price target on Bioventus (BVS) to $16 from $18 and keeps a Buy rating on the shares. The firm notes Bioventus reported Q3 revenue below expectations,

Barrington analyst Michael Petusky lowered the firm’s price target on Bioventus (BVS) to $16 from $18 and keeps an Outperform rating on the shares. The firm views the company’s Q3

Canaccord analyst William Plovanic lowered the firm’s price target on Bioventus (BVS) to $18 from $19 and keeps a Buy rating on the shares. The firm said they delivered a

Reports Q3 revenue $142.442M, consensus $149.52M. “Bioventus (BVS) delivered solid third-quarter results demonstrated by strong gross margin, operating cash flow and Adjusted EBITDA,” said Rob Claypoole, Bioventus President and Chief

For the twelve months ending December 31, 2026, the Company is: Presenting Adjusted Cash from Operations of $84M-$89M, which excludes the cash flow impact of the costs related to the

Bioventus, Inc. (BVS) is scheduled to report 3rd quarter earnings on 11/02/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect Bioventus, Inc. to post earnings of $0.15

Bioventus, Inc. (($BVS)) has held its Q2 earnings call. Read on for the main highlights of the call. Bioventus, Inc. struck an upbeat tone on its latest earnings call, highlighting

Canaccord raised the firm’s price target on Bioventus (BVS) to $19 from $15 and keeps a Buy rating on the shares. The firm updated its mode following Q2 results and
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 11, 2027TBA | $893.17M | $0.22 | $164.56M | -0.13 | 12.42 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.